




























NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

Niklas Klümper, MD^{1,2,3,4} ; Ngoc Khanh Tran^{1,2,3} ; Stefanie Zschäbitz, MD⁵; Oliver Hahn, MD⁶ ; Thomas Büttner, MD^{1,3} ; Florian Roghmann, MD^{4,7}; Christian Bolenz, MD^{4,8}; Friedemann Zengerling, MD^{4,8}; Constantin Schwab, MD⁹ ; Dora Nagy, MD^{3,10}; Marieta Toma, MD^{3,10} ; Glen Kristiansen, MD^{3,4,10}; Hendrik Heers, MD¹¹ ; Philipp Ivanyi, MD¹² ; Günter Niegisch, MD¹³ ; Camilla Marisa Grunewald, MD¹³ ; Christopher Darr, MD¹⁴ ; Arian Farid, MD¹⁵; Katrin Schlack, MD¹⁶ ; Mahmoud Abbas, MD¹⁷; Can Aydogdu, MD¹⁸ ; Jozefina Casuscelli, MD¹⁸; Theresa Mokry, MD¹⁹ ; Michael Mayr, MD²⁰; Dora Niedersüß-Beke, MD²¹; Steffen Rausch, MD²² ; Dimo Dietrich, PhD²³ ; Jonas Saal, MD^{2,3,24} ; Jörg Ellinger, MD^{1,3} ; Manuel Ritter, MD^{1,3,4} ; Abdullah Alajati, PhD^{1,3}; Christoph Kuppe, MD, PhD²⁵ ; Joshua Meeks, MD, PhD²⁶ ; Francisco E. Vera Badillo, MD²⁷ ; J. Alberto Nakauma-González, PhD²⁸ ; Joost Boormans, MD²⁸; Kerstin Junker, MD²⁹ ; Arndt Hartmann, MD^{4,30,31,32}; Viktor Grünwald, MD³³ ; Michael Hölzel, MD, PhD^{2,3} ; and Markus Eckstein, MD^{4,30,31,32} 

DOI <https://doi.org/10.1200/JCO.23.01983>

ABSTRACT

PURPOSE The anti-NECTIN4 antibody–drug conjugate enfortumab vedotin (EV) is approved for patients with metastatic urothelial cancer (mUC). However, durable benefit is only achieved in a small, yet uncharacterized patient subset. *NECTIN4* is located on chromosome 1q23.3, and 1q23.3 gains represent frequent copy number variations (CNVs) in urothelial cancer. Here, we aimed to evaluate *NECTIN4* amplifications as a genomic biomarker to predict EV response in patients with mUC.

MATERIALS AND METHODS We established a *NECTIN4*-specific fluorescence in situ hybridization (FISH) assay to assess the predictive value of *NECTIN4* CNVs in a multicenter EV-treated mUC patient cohort (mUC-EV, n = 108). CNVs were correlated with membranous *NECTIN4* protein expression, EV treatment responses, and outcomes. We also assessed the prognostic value of *NECTIN4* CNVs measured in metastatic biopsies of non-EV-treated mUC (mUC-non-EV, n = 103). Furthermore, we queried The Cancer Genome Atlas (TCGA) data sets (10,712 patients across 32 cancer types) for *NECTIN4* CNVs.

RESULTS *NECTIN4* amplifications are frequent genomic events in muscle-invasive bladder cancer (TCGA bladder cancer data set: approximately 17%) and mUC (approximately 26% in our mUC cohorts). In mUC-EV, *NECTIN4* amplification represents a stable genomic alteration during metastatic progression and associates with enhanced membranous *NECTIN4* protein expression. Ninety-six percent (27 of 28) of patients with *NECTIN4* amplifications demonstrated objective responses to EV compared with 32% (24 of 74) in the nonamplified subgroup ($P < .001$). In multivariable Cox analysis adjusted for age, sex, and Bellmunt risk factors, *NECTIN4* amplifications led to a 92% risk reduction for death (hazard ratio, 0.08 [95% CI, 0.02 to 0.34]; $P < .001$). In the mUC-non-EV, *NECTIN4* amplifications were not associated with outcomes. TCGA Pan-Cancer analysis demonstrated that *NECTIN4* amplifications occur frequently in other cancers, for example, in 5%–10% of breast and lung cancers.

CONCLUSION *NECTIN4* amplifications are genomic predictors of EV responses and long-term survival in patients with mUC.

ACCOMPANYING CONTENT

 Appendix

Accepted February 26, 2024

Published April 24, 2024

J Clin Oncol 42:2446-2455

© 2024 by American Society of
Clinical Oncology



[View Online
Article](#)

Licensed under the Creative
Commons Attribution 4.0 License

INTRODUCTION

The anti-NECTIN4 antibody–drug conjugate (ADC) enfortumab vedotin (EV) has been approved for previously treated patients with metastatic urothelial cancer (mUC).^{1,2} The combination of

EV plus pembrolizumab (EV/P) was recently approved in metastatic, treatment-naïve and cisplatin-ineligible patients with mUC. More recently, in EV-302, this combination proved to be superior to platinum plus gemcitabine and defined a new standard of care in the first-line setting.^{3–6}

CONTEXT

Key Objective

Can NECTIN4 amplifications be used as a genomic biomarker to predict the response to the anti-NECTIN4 antibody-drug conjugate (ADC) enfortumab vedotin (EV) in patients with metastatic urothelial cancer (mUC)?

Knowledge Generated

NECTIN4 amplifications were found to be frequent genomic events in mUC, occurring in approximately 25% of cases. In the EV-treated mUC patient cohort, 96% of patients with NECTIN4 amplifications showed objective responses to EV compared with 32% in the nonamplified subgroup. The frequent occurrence of NECTIN4 amplifications in various cancer types, for example, lung and breast cancers, indicates that this biomarker holds promise for tumor-agnostic clinical development of NECTIN4-targeted ADC.

Relevance (M.A. Carducci)

This hypothesis generating study requires prospective evaluation as a predictive genomic biomarker for EV responses. Given the target of EV as an anti-NECTIN4 ADC, the results are highly plausible and may represent strong classifier for treatment response and improved clinical outcomes.*

*Relevance section written by JCO Associate Editor Michael A. Carducci, MD, FACP, FASCO.

EV is currently administered in an all-comer setting without rational biomarker-based patient selection although there is evidence that its target NECTIN4 is heterogeneously expressed in urothelial cancer (UC) molecular subtypes.⁷⁻⁹ In addition, we recently showed that membranous NECTIN4 expression frequently decreased during metastatic spread and correlates with EV response in patients with mUC.¹⁰ In light of other effective treatment alternatives such as trophoblast cell surface antigen 2 (TROP2)- or human epidermal growth factor receptor 2 (HER2)-directed ADC or fibroblast growth factor receptor inhibitors, a better understanding of the molecular basis for EV responses is urgently needed to improve the rational use of this effective drug for patients with mUC¹¹⁻¹⁵ and to optimize its ongoing clinical development in earlier UC stages and other solid tumors.¹⁶⁻¹⁹

The relationship between copy number variation (CNV), mRNA, and protein expression has been known for decades. As a prime example, anti-HER2-targeted therapy conquered modern oncologic therapy of certain breast cancer subtypes and subsequently other entities in an unprecedented success story. The HER2-targeted ADC trastuzumab deruxtecan (T-DXd) proved to be effective in various HER2-expressing solid cancers, also mUC, with a close correlation with expression status.^{20,21} However, HER2-directed therapy is guided solely on the basis of biomarker testing that aims to identify HER2-over-expressing/*ERBB2*-amplified tumors. Unlike in this setting, anti-NECTIN4 EV, whose therapeutic efficacy has been shown to depend on the expression of its target,^{7,10} is applied without previous tumor biomarker testing. Similar to HER2, whose expression is strongly linked to CNV of *ERBB2*, previous reports linked *NECTIN4* gene expression to gains/amplifications of 1q23.3—where the *NECTIN4* gene is located—occurring in approximately 15%-20% of mUC²² with an enrichment of

NECTIN4 amplifications in luminal molecular subtypes of mUC.²³ Despite the frequency of *NECTIN4* CNVs in mUC, to date, the link between *NECTIN4* CNVs, membranous NECTIN4 protein expression, and especially the clinical potential of *NECTIN4* CNVs to predict EV responses has not been assessed.

Thus, we here assessed *NECTIN4* CNVs and their association with membranous NECTIN4 protein expression in a multi-center cohort of *n* = 108 EV-treated patients with mUC and correlated the results with EV responses and outcomes. Furthermore, we confirmed the correlation of *NECTIN4* CNVs, mRNA, and protein expression in a The Cancer Genome Atlas (TCGA) pan-cancer analysis and explored the prevalence of *NECTIN4* CNVs representing a potential tumor-agnostic genomic biomarker to predict EV response in multiple cancer entities.

MATERIALS AND METHODS

TCGA Data

CNV (Affymetrix single nucleotide polymorphism [SNP] 6.0 array data), transcriptome sequencing (RNA-Seq_v2, log₂-transformed RNA-Seq by expectation maximization [RSEM] normalized values), and reverse phase protein arrays (RPPA, only for TCGA-BRCA) were downloaded via cBioPortal²⁴ querying 10,712 samples/patients in a TCGA pan-cancer analysis including 32 studies. For the *n* = 408 bladder cancers from TCGA (TCGA-BLCA), clinical data (age, sex, outcomes) were downloaded from the University of California, Santa Cruz Xena browser.²⁵ The TCGA Network calculated CNVs using GISTIC 2.0, and the following values were assigned: -2 = deep deletion; -1 = shallow deletion; 0 = diploid; 1 = gain; 2 = amplification.

Multicenter EV-Treated mUC Cohort

We retrospectively reviewed medical records of $n = 108$ EV-treated patients with mUC. All patients received EV as the standard of care. Treatment response was evaluated according to RECIST v.1.1 by site investigators.²⁶ Progression-free survival (PFS) was defined as the time from EV initiation to radiologic or clinical progression or death from any cause. Representative formalin-fixed and paraffin-embedded (FFPE) tissue of the primary tumor (PRIM; transurethral resection of the bladder [TURB], cystectomy, or nephroureterectomy) and/or metastatic (MET) tissue was required for inclusion in our explorative biomarker study. When multiple tissue samples were available (matched PRIM + MET in $n = 27$), we considered the one closest to EV start for our outcome analyses. The study was approved by the ethical review board of the Friedrich-Alexander-University Erlangen-Nürnberg (approval numbers: 329_16B and 97_18Bc) and the Medical Faculty of the University of Bonn (approval number: 372/21). Our biomarker study conforms to REMARK guidelines.²⁷

Non-EV-Treated mUC Cohort

Whole-genome sequencing (WGS) was previously conducted on fresh-frozen metastatic biopsy samples from 116 patients with mUC.²³ These patients with mUC were enrolled in clinical trials (ClinicalTrials.gov identifiers: [NCT01855477](#) and [NCT02925234](#)) for palliative systemic treatments, with none receiving EV (mUC-non-EV). This patient cohort was already described in detail by Nakauma-González et al.²³ *NECTIN4* CNVs were assessed using GISTIC 2.0.²⁸ Sufficient clinical information on outcomes was available for $n = 103$ patients.

NECTIN4 Fluorescence In Situ Hybridization

The *NECTIN4* fluorescence in situ hybridization (FISH) probe was purchased from Empire Genomics (Catalog No. *NECTIN4*-20-GR, Empire Genomics, Buffalo, NY). The probe is designed to specifically target and bind to the *NECTIN4* gene (NCBI Gene ID: 81607). The probe consisted of a fluorescently labeled DNA probe that specifically binds to the *NECTIN4* gene. All hybridizations were performed in an accredited specialized laboratory for clinical molecular pathology (accredited according to DIN EN ISO/IEC 17020) using a standard protocol.

The slides were analyzed using a fluorescence microscope equipped with appropriate filter sets to detect the fluorescence signal from *NECTIN4* and *CEN1* probes. Representative tumor areas for formal analysis were chosen by an experienced board-certified pathologist (ME; blinded to patient outcomes), and at least 50 nonoverlapping nuclei per sample were assessed. Green (*NECTIN4*) and red (*CEN1*) signals were manually quantified. The *NECTIN4*/*CEN1* ratio was calculated, and a ratio of ≥ 2.0 qualified tumors as *NECTIN4*-amplified. Tumors with ratio values < 2.0 were considered nonamplified. Furthermore, gene copy changes (≥ 4 *NECTIN4*

gene copies per nucleus) without qualifying for an amplification (*NECTIN4*/*CEN1* ratio below < 2.0) were considered as polysome tumors, and polysomy status was correlated with response to EV.

NECTIN4 Immunohistochemistry

Immunohistochemical staining of *NECTIN4* was performed using a VENTANA BenchMark ULTRA autostainer (Ventana, Oro Valley, AZ), as previously described.¹⁰ The samples were categorized as negative (H-score, 0–14), weak (H-score, 15–99), moderate (H-score, 100–199), or strong (H-score, 200–300), as described previously.^{10,29}

SNP Array

DNA from the cryopreserved tumor specimen was isolated using the AllPrep DNA/RNA Micro Kit (#80284, Qiagen, Hilden, Germany) following the manufacturer's instructions. Infinium Global Screening Array-24 v3.0 Kit (Illumina, San Diego, CA) was used according to the manufacturer's protocol for the detection of *NECTIN4* CNVs. Data were analyzed using GenomeStudio version 2.0.5 (Illumina) with cnvPartition CNV Analysis Plugin version 3.2.0 to identify CNV regions and estimate CNV values. CNV values of higher than two were considered as amplification.

Statistical Analysis

Statistical analysis was performed using R (Version 4.3.0), R Studio (Version 2023.03.1 + 446), and GraphPad Prism (Version 9.4.0).

NECTIN4 CNV was correlated with *NECTIN4* mRNA (log₂-transformed RSEM-normalized values) and membranous protein expression (H-score). Nonparametric Mann-Whitney test was used to compare two groups. For comparisons involving multiple groups, the nonparametric Kruskal-Wallis test was used.

The predictive value of *NECTIN4* amplification for response to EV was assessed by comparing best overall response (BOR), progression-free survival (PFS), and overall survival (OS) between *NECTIN4*-amplified and nonamplified tumors.

To evaluate the survival after the start of EV treatment, univariable Kaplan-Meier regressions were performed, and significance was determined using the log-rank test. Multivariate Cox regression analyses were conducted to compare the prognostic value of *NECTIN4* CNV with baseline patient characteristics (age, sex) and the Bellmunt risk factors (Eastern Cooperative Oncology Group > 0 , hemoglobin level < 10 g/dL, and the presence of liver metastasis)³⁰ in relation to PFS and OS after EV initiation.

All *P* values were calculated as two-sided, and a significance level of $P < .05$ was used to determine statistical significance.

RESULTS

NECTIN4 Amplifications Predict Responses and Favorable Outcomes to EV in mUC

We first established a *NECTIN4* FISH assay to examine *NECTIN4* CNVs. FISH images and corresponding IHC stainings for a *NECTIN4* nonamplified UC lacking membranous *NECTIN4* expression and a *NECTIN4*-amplified UC that demonstrates pronounced membranous *NECTIN4* expression, respectively, are illustrated in **Figures 1A** and **1B**. The *NECTIN4* CNVs in these samples were validated using a SNP assay, which confirms the accuracy and specificity of our *NECTIN4* FISH assay (Appendix **Fig A1**, online only). Next, we used FISH to determine *NECTIN4* CNV in our multicenter EV-treated mUC cohort (mUC-EV, $n = 108$). Twenty-eight of 108 samples (26%) showed *NECTIN4* amplifications (*NECTIN4*/*CEN1* ratio ≥ 2.0), consistent with amplification frequencies

observed in the non-EV-treated metastatic biopsy mUC cohort (mUC-non-EV, 26%, 27 of 103). Regarding baseline characteristics, 25 of 28 patients with *NECTIN4* amplifications were male ($P = .043$) and tended to be older ($P = .20$; Appendix **Table A1**). In the mUC-non-EV cohort (ClinicalTrials.gov identifiers: [NCT01855477](#) and [NCT02925234](#)), 27 of 27 patients with *NECTIN4* amplification were male ($P = .001$), and again, there was a nonsignificant trend toward a higher frequency of *NECTIN4* amplification in older patients with mUC ($P = .069$; Appendix **Table A2**). In TCGA-BLCA, there was a significant correlation between *NECTIN4* amplification and older age ($P = .013$), and there was a nonsignificant trend toward higher amplification frequency in males ($P = .15$; Appendix **Table A3**). Next, we evaluated whether *NECTIN4* CNVs correlated with membranous *NECTIN4* protein expression, the prerequisite for EV binding, known to be correlated with EV response.¹⁰ *NECTIN4*-amplified tumors demonstrated significantly enhanced membranous *NECTIN4* expression (median H-score: 295;




FIG 1. *NECTIN4* amplification predicts EV response in mUC. (A and B) *NECTIN4* FISH image (green signals = *NECTIN4*; red signals = centromere 1, 1,000 \times oil immersion) and (A) corresponding immunohistochemical *NECTIN4* staining on *NECTIN4* nonamplified and (B) *NECTIN4*-amplified urothelial cancers. The gray dashed box demonstrates the two patient cases. (C) Membranous *NECTIN4* expression is significantly associated with FISH-detected *NECTIN4* amplification in our EV-treated UC cohort (mUC-EV). Statistical significance (***) was determined using the Mann-Whitney U test. (D) Sankey plot of *NECTIN4* amplification status in the 27 matched PRIM and MET samples. (E) Evolution of membranous *NECTIN4* expression during metastatic spread in the eight *NECTIN4*-amplified PRIMs. (F) BOR on the mUC-EV cohort on the basis of *NECTIN4* copy number status; BOR was available for $n = 65$ patients. *NECTIN4* amplification status is associated with both prolonged (G) PFS and (H) OS since EV therapy start compared with nonamplified tumors. (I) *NECTIN4* amplification is not associated with OS in non-EV-treated mUC. The log-rank P value is shown. The dashed lines demonstrate median PFS and OS when reached. BOR, best overall response; EV, enfortumab vedotin; FISH, fluorescence in situ hybridization; OS, overall survival; MET, metastatic; PFS, progression-free survival.

IQR, 235–300) compared with *NECTIN4* nonamplified tumors (median H-score, 90; IQR, 20–205; [Fig 1C](#)). In 27 matched primary (PRIM) and corresponding metastatic (MET) tumor tissues, *NECTIN4* CNV was stable in 93% (25 of 27). Of eight *NECTIN4*-amplified PRIM with available matched MET, only one tumor lost *NECTIN4* amplification during metastasis ([Fig 1D](#)). Membranous *NECTIN4* expression of *NECTIN4*-amplified PRIM (median H-score, 290; range, 170–300) remained high in the corresponding MET (median H-score, 280; range, 20–300), except for the primary tumor, which lost its *NECTIN4* amplification ([Fig 1E](#)). In only 1 of 27 matched PRIM and MET pairs, *NECTIN4* amplification was exclusive in the metastatic sample ([Fig 1D](#)).

A total of 96% (27 of 28) patients with *NECTIN4* amplification demonstrated an objective response (82%; partial response [PR] and 14% complete response [CR], one patient with stable disease [SD]) as BOR compared with 32% (including 3% with CR) of the *NECTIN4* nonamplified tumors (Chi square $P < .001$; [Fig 1F](#)). *NECTIN4* amplifications associated with prolonged PFS ([Fig 1G](#)) and OS ([Fig 1H](#)), with 90% 12-month survival rate and median OS not reached (95% CI, NR to NR) compared with 41% 12-month survival and a median OS of 8.8 months (95% CI, 6.1 to 14) for *NECTIN4* nonamplified tumors. In multivariable Cox regression coadjusted for age, sex, and Bellmunt risk factors, *NECTIN4* amplification status led to a 92% risk reduction for death compared with *NECTIN4* nonamplified tumors (hazard ratio, 0.08 [95% CI, 0.02 to 0.34], $P < .001$; [Table 1](#)). In addition,

NECTIN4 amplification was associated with prolonged PFS and OS compared with the patient subgroup of nonamplified tumors with strong membranous *NECTIN4* expression (H-score ≥ 200 ; [Appendix Fig A2](#)). Furthermore, we explored whether polysome gene copy changes per nucleus (copy number ≥ 4.0) without qualifying for an amplification (*NECTIN4*/*CEN1* ratio below <2.0) correlated with EV response and found that five of eight polysome tumors demonstrated an PR/CR or SD with disease control >6 months.

To rule out a prognostic bias of *NECTIN4* CNVs, we assessed their prognostic impact in non-EV-treated UC patient cohorts. In the mUC-non-EV cohort, *NECTIN4* amplifications were assessed via whole-genome DNA sequencing in 103 metastatic biopsy samples obtained before palliative systemic treatment. In this cohort, *NECTIN4* amplifications were found in 26% of tumors and were not associated with OS ([Fig 1I](#)). In the TCGA-BLCA cohort of muscle-invasive bladder cancer, *NECTIN4* amplifications were also not associated with disease-specific survival and OS ([Appendix Fig A3A](#) and [A3B](#)).

NECTIN4 Amplification Occurs Frequently Across Entities

In the TCGA Pan-Cancer cohort, *NECTIN4* amplifications were observed in 25 of 32 cancer types including various solid entities with *NECTIN4* amplification frequency $> 5\%$ ([Fig 2A](#)).

TABLE 1. Multivariable Cox Regression Analyses in the Multicenter Enfortumab Vedotin Cohort

Characteristic	PFS				OS			
	No.	HR	95% CI	<i>P</i>	No.	HR	95% CI	<i>P</i>
<i>NECTIN4</i> CNV status				<.001				<.001
Nonamplified	80	—	—		80	—	—	
Amplified	28	0.14	0.06 to 0.30		28	0.08	0.02 to 0.34	
Age, years				.25				.71
<75	86	—	—		86	—	—	
≥ 75	22	0.70	0.38 to 1.30		22	1.16	0.54 to 2.47	
Sex				.28				.58
Male	81	—	—		81	—	—	
Female	27	1.36	0.79 to 2.34		27	0.83	0.41 to 1.65	
Liver metastasis				.31				.023
No	76	—	—		76	—	—	
Yes	32	0.77	0.46 to 1.29		32	2.06	1.11 to 3.82	
ECOG				.090				<.001
0	36	—	—		36	—	—	
≥ 1	72	1.53	0.92 to 2.55		72	4.84	2.01 to 11.7	
Hemoglobin, g/dL				.54				.16
≥ 10	104	—	—		104	—	—	
<10	4	0.71	0.23 to 2.19		4	0.29	0.04 to 2.24	

NOTE. Significant *P* values are highlighted in bold.

Abbreviations: CNV, copy number variation; ECOG, Eastern Cooperative Oncology Group; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.

The highest prevalence of *NECTIN4* amplifications was found in bladder cancer (BLCA, 17%), cholangiocarcinoma (CHOL, 14%), hepatocellular carcinoma (LIHC, 12%), breast cancer (BRCA, 9%), and lung adenocarcinoma (LUAD, 7%). *NECTIN4*-amplified samples or those with gains showed increased *NECTIN4* mRNA levels compared with diploid samples (Fig 2B) on the pan-cancer level. In BLCA, BRCA, and LUAD—where EV is approved or in late-stage clinical development—*NECTIN4* amplifications associated with increased *NECTIN4* mRNA expression (Fig 2C; Appendix Figs A4A and A4C) and higher *NECTIN4* protein levels in breast cancer (Appendix Fig A4B).

DISCUSSION

The identification of biomarkers to predict response to targeted therapies is crucial to improve the management of patients with cancer.³² Here, we provide data from a multicenter mUC patient cohort highlighting *NECTIN4* amplifications as genomic biomarkers to predict EV responses and favorable outcomes. Importantly, in the non-EV-treated patients with mUC, *NECTIN4* amplifications have no impact on OS,³³ suggesting that *NECTIN4* amplifications are

neither indicating aggressive nor favorable tumor biology, strengthening its potential value as a pure predictive biomarker.³⁴ *NECTIN4* amplification was strongly associated with EV sensitivity (BOR, 96%). However, the response rate of 32% in the nonamplified subgroup is comparable with the expected outcomes (BOR app. 40%) observed in real-world settings and the pivotal phase III EV-301 study.^{1,35,36} With a median OS of 12 months (95% CI, 9.7 to NR) in our mUC-EV cohort, our data confirm the clinical activity of EV in previously treated patients with mUC (eg, EV-301, 12.9 months [95% CI, 10.6 to 15.2]). Therefore, EV again proves to be an effective drug in previously treated mUC also in the non-amplified context.

We recently showed that membranous *NECTIN4* protein expression is volatile and often (>50%) decreases during metastatic progression of mUC.¹⁰ By contrast, 88% of PRIM with *NECTIN4* amplifications retains their *NECTIN4* amplification and subsequently a stable high membranous *NECTIN4* protein expression during metastatic progression. This is in line with previous results from the study by Faltas et al³⁷ demonstrating that early acquired genomic features including copy number alterations are rather stable during




FIG 2. *NECTIN4* amplifications occur frequently across solid tumors. (A) The frequency of *NECTIN4* amplifications are depicted for 32 studies consisting of 10,712 samples/patients, with BLCA presenting the highest prevalence (17%). Positive correlation was observed between *NECTIN4* copy number variation and mRNA level in both (B) Pan-Cancer Study and (C) TCGA-BLCA. Standard TCGA study abbreviations were used.³¹ BLCA, Bladder Urothelial Carcinoma; TCGA, The Cancer Genome Atlas.

metastatic progression in comparison with parental primary tumors. Thus, treatment decisions for the metastatic stage could be based on *NECTIN4* amplification status in primary tumor material, facilitating implementation into clinical trials. It is worth noting that this consideration does not apply to the assessment of membranous *NECTIN4* protein expression, which decreases substantially during metastasis in UC without *NECTIN4* amplifications.¹⁰ This difference could be explained by the inability of *NECTIN4*-amplified tumors to downregulate membranous expression of *NECTIN4* at the transcriptional level. Because downregulation of the target is a known mechanism of resistance to ADCs,^{38,39} this could explain, at least in part, the exceptional and durable clinical efficacy of EV in *NECTIN4*-amplified tumors. Beside considerations of tissue choice for predictive biomarker testing, overcoming hurdles to implement biomarker tests into daily care is a major obstacle for biomarker-guided therapies. In the case of CNV assessment, a broad variety of cytogenetic and molecular techniques are available, including FISH/chromogenic in situ hybridization, SNP microarray, comparative genomic hybridization, multiplex ligation-dependent probe amplification, and sequencing methods like whole-exome or whole-genome sequencing.⁴⁰ Among these options, FISH is the most frequently performed diagnostic assay to assess CNVs in clinical routine.⁴¹ Moreover, FISH as predictive biomarker assay has been proven to be a highly reproducible, easy-to-implement, fast, and cost-effective method in daily molecular pathology. Thus, we conclude that a *NECTIN4* FISH assay could be quickly integrated into clinical trials and routine molecular pathology/daily patient care.

Other biomarkers were described to be associated with EV response and outcomes: Jindal et al⁴² conducted a comprehensive biomarker analysis within the UNITE study cohort, which comprised 303 patients receiving EV monotherapy with available next-generation sequencing data across 16 US sites. Among these patients, 207 had their tumor mutational burden (TMB) assessed and 146 had their PD-L1 status evaluated. Multivariate analysis revealed that alterations in *ERBB2*, *KDM6A*, and *PIK3CA* were associated with favorable treatment outcomes on EV. Conversely, patients with low TMB (<10 Mut/Mb) and high PD-L1 (CPS ≥10) exhibited less favorable outcomes on EV.⁴² It is known that alterations in *ERBB2* and *KDM6A* are overrepresented in luminal differentiated UC,⁴³ which are known to be enriched for *NECTIN4* amplification²³ and increased *NECTIN4* mRNA and protein expression.^{7,44} Therefore, the prognostic value of these genomic alterations may depend on luminal differentiation and concomitant higher *NECTIN4* expression. Consistent with this, the absence of squamous differentiation has been shown to correlate with response to EV.⁴⁵ In addition, the occurrence of skin toxicity after initiation of EV treatment has been reported to be associated with favorable outcomes of EV treatment.⁴⁶ In the context of ADC precision oncology, it is well established from several clinical trials that ADC

response correlates with the respective target gene expression, for example, for HER2^{14,20,21} and FOLR1-targeting ADC⁴⁷; we have demonstrated linear correlation also between membranous *NECTIN4* expression and EV response.¹⁰ Future biomarker analyses would therefore ideally need to integrate membranous *NECTIN4* expression, *NECTIN4* CNV, histomorphology, and further high throughput data to deepen our understanding of EV-responsive tumors.

Rational biomarker-guided therapy selection is urgently required to establish the optimal therapy sequence for patients with (m)UC.^{11,13,32,48} Consideration of *NECTIN4* amplifications as predictive biomarkers could potentially rationalize EV drug development—also at earlier disease stages—by defining the patient subgroup with the highest chance of durable benefit. In this context, a strategic focus on biomarker-guided trials could greatly enhance our understanding of the potential of EV or other anti-*NECTIN4*-targeted therapies and open new avenues to optimize treatment and improve outcomes in patients with (m) UC.^{48,49}

A wide range of surface targets, such as HER2 or TROP2, are present in different types of cancers, and there has been a growing interest to expand the use of ADC beyond specific cancer types in a tumor-agnostic fashion.^{16,17,50,51} Of note, in our TCGA Pan-Cancer analysis, *NECTIN4* amplifications can be found in 5%-10% of breast cancer and non-small cell lung cancer, both tumor types with a high impact on all-cancer mortality, which are currently being evaluated for EV response in the multicohort phase II EV-202 trial (ClinicalTrials.gov identifier: [NCT04225117](https://clinicaltrials.gov/ct2/show/study?term=NCT04225117)).¹⁹ Thus, *NECTIN4* CNV may be a valuable predictive biomarker to streamline clinical development of *NECTIN4*-targeted therapies in tumor entities beyond UC.⁵² The frequent occurrence of *NECTIN4* amplifications across solid cancer types could thus pave the way for basket trial designs studying the efficacy of EV on the basis of *NECTIN4* CNV status in a tumor-agnostic study framework,^{16,17} similar to the phase II DESTINY-PanTumor02 trial which assessed anti-HER2 ADC T-DXd in HER2-expressing solid tumors.²⁰

Although our study certainly has important strengths, its main limitation is the use of a retrospectively assembled patient cohort, which consists of both archived primary (TURB, cystectomy or nephroureterectomy) and metastatic tumor specimens with varying ranges between tumor sampling and start of EV treatment. Therefore, our data are hypothesis-generating and prospective confirmation in larger, biomarker-driven trials is mandatory. As the combination of EV/P is the new standard of care in the first-line treatment of mUC, the predictive value of *NECTIN4* amplification in this new treatment setting should be further investigated. In addition, our study does not include correlative data on *NECTIN4* CNVs and responses to EV in other cancer entities, as mUC is the only approved standard-of-care setting for EV to date.

In conclusion, our study suggests that *NECTIN4* amplification is a simple, valuable, and easy-to-implement predictive biomarker for EV in patients with mUC. The frequent occurrence of *NECTIN4* amplifications in other

cancer types suggests that this biomarker is a promising candidate with broader applicability for clinical development of *NECTIN4*-targeted ADCs in a tumor-agnostic context.

AFFILIATIONS

¹Department of Urology and Pediatric Urology, University Hospital Bonn, Bonn, Germany

²Institute of Experimental Oncology, University Medical Center Bonn (UKB), Bonn, Germany

³Center for Integrated Oncology Aachen/Bonn/Cologne/Düsseldorf (CIO-ABCD), Bonn, Germany

⁴BRIDGE-Consortium Germany e.V., Mannheim, Germany

⁵Department of Medical Oncology, National Center for Tumor Disease (NCT), University Hospital, Heidelberg, Germany

⁶Department of Urology and Pediatric Urology, Julius Maximilians University Medical Center of Würzburg, Würzburg, Germany

⁷Department of Urology, Marien Hospital, Ruhr-University Bochum, Herne, Germany

⁸Department of Urology and Pediatric Urology, University Hospital Ulm, University of Ulm, Ulm, Germany

⁹Institute of Pathology, University of Heidelberg, Heidelberg, Germany

¹⁰Institute of Pathology, University Hospital Bonn, Bonn, Germany

¹¹Department of Urology, University Hospital Marburg, Marburg, Germany

¹²Department of Hemostaseology, Oncology and Stem Cell Transplantation, Medical University Hannover, Hannover, Germany

¹³Department of Urology, University Hospital Düsseldorf, Düsseldorf, Germany

¹⁴Department of Urology, University Hospital Essen, Essen, Germany

¹⁵Department of Urology, University Medical Center Göttingen, Göttingen, Germany

¹⁶Department of Urology, University Hospital Münster, Münster, Germany

¹⁷Department of Pathology, University Hospital Münster, Münster, Germany

¹⁸Department of Urology, University Hospital, Ludwig Maximilian University of Munich, Munich, Germany

¹⁹Department of Diagnostic and Interventional Radiology, Heidelberg University Hospital, Heidelberg, Germany

²⁰Clinic Ottakring, Institute of Pathology and Microbiology, Wien, Austria

²¹Department of Internal Medicine I, Wilhelminenspital, Wien, Austria

²²Department of Urology, Eberhard Karls University, Tübingen, Germany

²³Department of Otorhinolaryngology, University Medical Center Bonn (UKB), Bonn, Germany

²⁴Medical Clinic III for Oncology, Hematology, Immune-Oncology and Rheumatology, University Medical Center Bonn (UKB), Bonn, Germany

²⁵Institute of Experimental Medicine and Systems Biology and Division of Nephrology, RWTH Aachen University, Aachen, Germany

²⁶Department of Urology, Feinberg School of Medicine, Chicago, IL

²⁷Department of Medical Oncology, Queen's University, Kingston, Ontario, Canada

²⁸Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Rotterdam, the Netherlands

²⁹Department of Urology and Pediatric Urology, Saarland University, Homburg, Germany

³⁰Institute of Pathology, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg (FAU), Erlangen, Germany

³¹Comprehensive Cancer Center EMN, University Hospital Erlangen, Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

³²Bavarian Center for Cancer Research (Bayerisches Zentrum für Krebsforschung, BZKF), Erlangen, Germany

³³Clinic for Internal Medicine (Tumor Research) and Clinic for Urology, Interdisciplinary Genitourinary Oncology at the West-German Cancer Center, Essen University Hospital, Essen, Germany

CORRESPONDING AUTHOR

Niklas Klümper, MD; Twitter: @niklas_kluemper; e-mail: niklas.kluemper@ukbonn.de.

DISCLAIMER

The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

EQUAL CONTRIBUTION

N.K. and N.K.T. contributed equally to this work. M.H. and M.E. are joint senior authors.

SUPPORT

Supported by the BMBF-funded Advanced Clinician Scientist Program Bonn (ACCENT) of the Medical Faculty of the University of Bonn (grant ID: 01EO2107; N.K.) and the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) Young Investigator Academy UroAgeCare (grant ID: 511985506; N.K.); the DFG under Germany's Excellence Strategy (EXC2151–390873048; M.H.); and by the Else Kröner-Fresenius Foundation/EKFS (2020_EKEA.129; 2023_EKES.07; M.E.), the Clinician Scientist program of the IZKF of the FAU, the TOPECS funding line of the IZKF (T04) of the FAU, an advanced research grant of the IZKF of the FAU Erlangen-Nürnberg (IZKF-FAU D41; M.E.), and a Young Clinical Scientist Fellowship of the Bavarian Center for Cancer Research (BZKF; YSF-TP01; M.E.).

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at DOI <https://doi.org/10.1200/JCO.23.01983>.

DATA SHARING STATEMENT

The results are in part based upon publicly available data generated by the TCGA Research Network: <https://www.cancer.gov/tcga>. Further data that support the findings of this study are available from the corresponding author upon reasonable request.

AUTHOR CONTRIBUTIONS

Conception and design: Niklas Klümper, Ngoc Khanh Tran, Christian Bolenz, Steffen Rausch, Manuel Ritter, Arndt Hartmann, Michael Hölzel, Markus Eckstein

Financial support: Niklas Klümper, Arndt Hartmann, Michael Hölzel, Markus Eckstein

Administrative support: Niklas Klümper, Ngoc Khanh Tran, Florian Roghmann, Christian Bolenz, Manuel Ritter, Arndt Hartmann, Michael Hölzel, Markus Eckstein

Provision of study materials or patients: Niklas Klümper, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Marieta Toma, Glen Kristiansen, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Christopher Darr, Arian Farid, Can Aydogdu, Dora Niedersüß-Beke, Steffen Rausch, Jonas Saal, Jörg Ellinger, Manuel Ritter, Markus Eckstein

Collection and assembly of data: Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Thomas Büttner, Florian Roghmann, Christian Bolenz, Friedemann Zengerling, Constantin Schwab, Dora Nagy, Marieta Toma, Hendrik Heers, Philipp Ivanyi, Günter Niegisch, Camilla Marisa Grunewald, Christopher Darr, Arian Farid, Katrin Schlack,

Mahmoud Abbas, Can Aydogdu, Jozefina Casuscelli, Michael Mayr, Dora Niedersüß-Beke, Steffen Rausch, Jonas Saal, J. Alberto Nakauma-González, Arndt Hartmann, Viktor Grünwald, Michael Hölzel, Markus Eckstein

Data analysis and interpretation: Niklas Klümper, Ngoc Khanh Tran, Stefanie Zschäbitz, Oliver Hahn, Florian Roghmann, Christian Bolenz, Glen Kristiansen, Philipp Ivanyi, Theresa Mokry, Steffen Rausch, Dimo Dietrich, Jörg Ellinger, Manuel Ritter, Abdullah Alajati, Christoph Kuppe, Joshua Meeks, Francisco E. Vera Badillo, Joost Boormans, Kerstin Junker, Arndt Hartmann, Michael Hölzel, Markus Eckstein

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

ACKNOWLEDGMENT

We thank the patients and their families who were patients of this study. We thank the BioBank initiatives of the participating centers for their support of this study. In addition, we would like to thank the NGS Core Facility of the Medical Faculty at the University of Bonn and the TCGA Research Network.

REFERENCES

- Powles T, Rosenberg JE, Sonpavde GP, et al: Enfortumab vedotin in previously treated advanced urothelial carcinoma. *N Engl J Med* 384:1125-1135, 2021
- Yu EY, Petrylak DP, O'Donnell PH, et al: Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV-201): A multicentre, single-arm, phase 2 trial. *Lancet Oncol* 22:872-882, 2021
- Hoimes CJ, Flaig TW, Milowsky MI, et al: Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. *J Clin Oncol* 41:22-31, 2023
- O'Donnell PH, Milowsky MI, Petrylak DP, et al: Enfortumab vedotin with or without pembrolizumab in cisplatin-ineligible patients with previously untreated locally advanced or metastatic urothelial cancer. *J Clin Oncol* 41:4107-4117, 2023
- Powles TB, Perez Valderrama B, Gupta S, et al: LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC). *Ann Oncol* 34:S1340, 2023
- UC trials get standing ovation. *Cancer Discov* 13:2496, 2023
- Chu CE, Sjöström M, Egusa EA, et al: Heterogeneity in NECTIN4 expression across molecular subtypes of urothelial cancer mediates sensitivity to enfortumab vedotin. *Clin Cancer Res* 27:5123-5130, 2021
- Hoffman-Censits J, Lombardo K, McConkey D, et al: New and topics: Enfortumab vedotin mechanisms of response and resistance in urothelial cancer—What do we understand so far? *Urol Oncol* 39:619-622, 2021
- Heath EI, Rosenberg JE: The biology and rationale of targeting nectin-4 in urothelial carcinoma. *Nat Rev Urol* 18:93-103, 2021
- Klümper N, Ralsler DJ, Ellinger J, et al: Membranous NECTIN-4 expression frequently decreases during metastatic spread of urothelial carcinoma and is associated with enfortumab vedotin resistance. *Clin Cancer Res* 29:1496-1505, 2023
- Tagawa ST, Balar AV, Petrylak DP, et al: TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors. *J Clin Oncol* 39:2474-2485, 2021
- Loriot Y, Necchi A, Park SH, et al: Erdafitinib in locally advanced or metastatic urothelial carcinoma. *N Engl J Med* 381:338-348, 2019
- Loriot Y, Matsubara N, Park SH, et al: Phase 3 THOR study: Results of erdafitinib (erda) versus chemotherapy (chemo) in patients (pts) with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor alterations (*FGFRalt*). *J Clin Oncol* 41, 2023 (suppl 17; abstr LBA4619)
- Sheng X, Wang L, He Z, et al: Efficacy and safety of disitamab vedotin in patients with human epidermal growth factor receptor 2–positive locally advanced or metastatic urothelial carcinoma: A combined analysis of two phase II clinical trials. *J Clin Oncol* 42:1391-1402, 2024
- Miller EJ, Galsky MD: Precision medicine in urothelial carcinoma: Current markers to guide treatment and promising future directions. *Curr Treat Options Oncol* 24:1870-1888, 2023
- Corti C, Antonarelli G, Valenza C, et al: Histology-agnostic approvals for antibody–drug conjugates in solid tumours: Is the time ripe? *Eur J Cancer* 171:25-42, 2022
- Tarantino P, Carmagnani Pestana R, Corti C, et al: Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies. *CA Cancer J Clin* 72:165-182, 2022
- Chatterjee S, Sinha S, Kundu CN: Nectin cell adhesion molecule-4 (NECTIN-4): A potential target for cancer therapy. *Eur J Pharmacol* 911:174516, 2021
- Bruce JY, Pusztai L, Braith FS, et al: EV-202: A phase II study of enfortumab vedotin in patients with select previously treated locally advanced or metastatic solid tumors. *J Clin Oncol* 38, 2020 (suppl 15; abstr TPS3647)
- Meric-Bernstam F, Makker V, Oaknin A, et al: Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing solid tumors: Primary results from the DESTINY-PanTumor02 phase II trial. *J Clin Oncol* 42:47-58, 2024
- Mosele F, Deluche E, Lusque A, et al: Trastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: The phase 2 DAISY trial. *Nat Med* 29:2110-2120, 2023
- Riester M, Werner L, Bellmunt J, et al: Integrative analysis of 1q23.3 copy-number gain in metastatic urothelial carcinoma. *Clin Cancer Res* 20:1873-1883, 2014
- Nakauma-González JA, Rijnders M, van Riet J, et al: Comprehensive molecular characterization reveals genomic and transcriptomic subtypes of metastatic urothelial carcinoma. *Eur Urol* 81:331-336, 2022
- Cerami E, Gao J, Dogrusoz U, et al: The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov* 2:401-404, 2012 [Erratum: *Cancer Discov* 2:960, 2012]
- Goldman MJ, Craft B, Hastie M, et al: Visualizing and interpreting cancer genomics data via the Xena platform. *Nat Biotechnol* 38:675-678, 2020
- Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). *Eur J Cancer* 45:228-247, 2009
- McShane LM, Altman DG, Sauerbrei W, et al: Reporting recommendations for tumor marker prognostic studies. *J Clin Oncol* 23:9067-9072, 2005
- Mermel CH, Schumacher SE, Hill B, et al: GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. *Genome Biol* 12:R41, 2011
- Challita-Eid PM, Satpayev D, Yang P, et al: Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models. *Cancer Res* 76:3003-3013, 2016
- Bellmunt J, Choueiri TK, Fougeray R, et al: Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens. *J Clin Oncol* 28:1850-1855, 2010
- Grossman RL, Heath AP, Ferretti V, et al: Toward a shared vision for cancer genomic data. *N Engl J Med* 375:1109-1112, 2016
- Wahida A, Buschhorn L, Fröhling S, et al: The coming decade in precision oncology: Six riddles. *Nat Rev Cancer* 23:43-54, 2023
- Liu J, Lichtenberg T, Hoadley KA, et al: An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. *Cell* 173:400-416.e11, 2018
- Ballman KV: Biomarker: Predictive or prognostic? *J Clin Oncol* 33:3968-3971, 2015

35. Zschäbitz S, Biernath N, Hilser T, et al: Enfortumab vedotin in metastatic urothelial carcinoma: Survival and safety in a European multicenter real-world patient cohort. *Eur Urol Open Sci* 53:31-37, 2023
36. Koshkin VS, Henderson N, James M, et al: Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study. *Cancer* 128:1194-1205, 2022
37. Faltas BM, Prandi D, Tagawa ST, et al: Clonal evolution of chemotherapy-resistant urothelial carcinoma. *Nat Genet* 48:1490-1499, 2016
38. Coates JT, Sun S, Leshchiner I, et al: Parallel genomic alterations of antigen and payload targets mediate polyclonal acquired clinical resistance to sacituzumab govitecan in triple-negative breast cancer. *Cancer Discov* 11:2436-2445, 2021
39. Loganzo F, Tan X, Sung M, et al: Tumor cells chronically treated with a trastuzumab-maytansinoid antibody-drug conjugate develop varied resistance mechanisms but respond to alternate treatments. *Mol Cancer Ther* 14:952-963, 2015
40. Pös O, Radvanszky J, Buglyó G, et al: DNA copy number variation: Main characteristics, evolutionary significance, and pathological aspects. *Biomed J* 44:548-559, 2021
41. Bayle A, Bonastre J, Chaltiel D, et al: ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe. *Ann Oncol* 34:934-945, 2023
42. Jindal T, Zhang L, Jiang C, et al: Independent biomarkers predictive of outcomes with enfortumab vedotin (EV) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of the UNITE study. *J Clin Oncol* 41, 2023 (suppl 16; abstr 4573)
43. Kamoun A, de Reyniès A, Allory Y, et al: A consensus molecular classification of muscle-invasive bladder cancer. *Eur Urol* 77:420-433, 2020
44. Bahlinger V, Branz A, Strissel PL, et al: Associations of *TACSTD2/TROP2* and *NECTIN-4/NECTIN-4* with molecular subtypes, PD-L1 expression, and FGFR3 mutational status in two advanced urothelial bladder cancer cohorts. *Histopathology* 84:863-876, 2024
45. Jindal T, Zhang L, Deshmukh P, et al: Impact of squamous histology on clinical outcomes and molecular profiling in metastatic urothelial carcinoma PatientsTreated with immune checkpoint inhibitors or enfortumab vedotin. *Clin Genitourin Cancer* 21:e394-e404, 2023
46. Vlachou E, Matoso A, McConkey D, et al: Enfortumab vedotin-related cutaneous toxicity and radiographic response in patients with urothelial cancer: A single-center experience and review of the literature. *Eur Urol Open Sci* 49:100-103, 2023
47. Moore KN, Oza AM, Colombo N, et al: Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: Primary analysis of FORWARD I. *Ann Oncol* 32:757-765, 2021
48. Hu C, Dignam JJ: Biomarker-driven oncology clinical trials: Key design elements, types, features, and practical considerations. *JCO Precis Oncol* [10.1200/PO.19.00086](https://doi.org/10.1200/PO.19.00086)
49. Reardon B, Moore ND, Moore NS, et al: Integrating molecular profiles into clinical frameworks through the Molecular Oncology Almanac to prospectively guide precision oncology. *Nat Cancer* 2:1102-1112, 2021
50. Criscitiello C, Morganti S, Curigliano G: Antibody-drug conjugates in solid tumors: A look into novel targets. *J Hematol Oncol* 14:20, 2021
51. Uzunpamuk B, Haymaker C, Raso G, et al: HER2-low expression in patients with advanced or metastatic solid tumors. *Ann Oncol* 34:1035-1046, 2023
52. Boulefour W, Guillot A, Magné N: The anti-nectin 4: A promising tumor cells target. A systematic review. *Mol Cancer Ther* 21:493-501, 2022

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

NECTIN4 Amplification Is Frequent in Solid Tumors and Predicts Enfortumab Vedotin Response in Metastatic Urothelial Cancer

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/jco/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians ([Open Payments](#)).

Niklas Klümper

Stock and Other Ownership Interests: Bicycle Therapeutics, Pfizer, Daiichi Sankyo/UCB Japan, immatics
Honoraria: Astellas Pharma, MSD Oncology
Consulting or Advisory Role: Astellas Pharma, MSD Oncology, Eisai
Travel, Accommodations, Expenses: Ipsen, Photocure, MSD Oncology

Stefanie Zschäbitz

Honoraria: Amgen, Eisai Germany, Merck Serono, Pfizer (Inst), MSD Oncology, BMS GmbH & Co KG, Janssen Oncology, Ipsen, Astellas Pharma, Novartis, Bayer
Consulting or Advisory Role: Pfizer (Inst), MSD Oncology, Merck, Sanofi/Aventis (Inst), EUSA Pharma, Roche, Bristol Myers Squibb (Inst), Eisai, Amgen, Astellas Pharma (Inst), Ipsen, Bayer (Inst), Gilead Sciences
Research Funding: Eisai (Inst)
Travel, Accommodations, Expenses: Merck, Pfizer, BMS GmbH & Co KG, Ipsen, Amgen, Astellas Pharma, Janssen Oncology

Oliver Hahn

Honoraria: Bayer, Bristol Myers Squibb, AstraZeneca, Eisai Germany, Medac, Merck
Consulting or Advisory Role: AstraZeneca, Bayer, Bristol Myers Squibb, Eisai
Travel, Accommodations, Expenses: Bayer

Thomas Büttner

Honoraria: Astellas Pharma
Travel, Accommodations, Expenses: Ipsen, MSD

Florian Roghmann

Consulting or Advisory Role: Janssen (Inst), BMS (Inst), Roche (Inst), Pfizer, Merck Serono (Inst), Merck (Inst), Astellas Pharma (Inst)
Travel, Accommodations, Expenses: Janssen (Inst), Merck Serono (Inst)

Christian Bolenz

Honoraria: Janssen-Cilag GmbH, AstraZeneca, Bayer, Bristol Myers Squibb
Consulting or Advisory Role: AstraZeneca, Bristol Myers Squibb
Research Funding: ERBE Elektromedizin (Inst), Thericon GmbH, AstraZeneca (Inst)
Travel, Accommodations, Expenses: Janssen Cilag
Uncompensated Relationships: Thericon GmbH

Friedemann Zengerling

Honoraria: Ipsen, Pfizer, Astellas Pharma, Janssen, Merck, Bayer/Vital, Amgen, Apogepha
Consulting or Advisory Role: Bristol Myers Squibb, IPSEN, Merck Sharp & Dohme, Bayer Health, Apogepha, Pfizer, Janssen, Roche, AstraZeneca, Merck, Astellas Pharma, Novartis
Travel, Accommodations, Expenses: Astellas Pharma, IPSEN, Janssen, Pfizer

Constantin Schwab

Stock and Other Ownership Interests: Illumina, Novo Nordisk
Honoraria: MSD, Bayer Germany

Marieta Toma

Honoraria: Gilead Sciences

Hendrik Heers

Honoraria: Janssen, Merck/Pfizer, BMS GmbH & Co KG, AstraZeneca
Consulting or Advisory Role: Novartis, Bayer
Research Funding: BMS GmbH & Co KG (Inst), Ipsen (Inst), Pfizer (Inst), Merck Serono (Inst)
Travel, Accommodations, Expenses: Merck/Pfizer, Janssen

Philipp Ivanyi

Stock and Other Ownership Interests: BB Biotech Ventures
Honoraria: Bayer/Vital, Bristol Myers Squibb, Ipsen, Eisai, AIMM Therapeutics, EUSA Pharma, Roche Pharma AG, MSD Oncology, Merck Serono, AstraZeneca
Consulting or Advisory Role: Bayer/Vital, Bristol Myers Squibb, Ipsen, Merck Serono, Pfizer, MSD, Eisai, ClinSol, Deciphera, EUSA Pharma
Travel, Accommodations, Expenses: Bristol Myers Squibb, Ipsen, Merck Serono
Other Relationship: Merck Serono, Pfizer
Uncompensated Relationships: German Cancer Society, AIO-Studien

Günter Niegisch

Honoraria: Roche Pharma AG, Medac, AstraZeneca, Astellas Pharma, Pfizer, BMS GmbH & Co KG, Eisai Germany, Janssen Oncology
Consulting or Advisory Role: Roche Pharma AG, Bristol Myers Squibb, Janssen Oncology, Pfizer, Merck/Pfizer, Astellas Pharma, AstraZeneca
Travel, Accommodations, Expenses: Janssen Oncology, Roche, AstraZeneca

Camilla Marisa Grunewald

Consulting or Advisory Role: Ferring

Christopher Darr

Honoraria: Janssen, Ipsen, Bayer
Consulting or Advisory Role: Janssen, Ipsen
Research Funding: Deutsche Forschungsgemeinschaft (Inst)
Travel, Accommodations, Expenses: Ipsen, Janssen, Bayer

Katrin Schlack

Honoraria: AAA HealthCare, Amgen (Inst), Astellas Pharma, AstraZeneca, Bayer Germany, Eisai Germany, Fosanis, Ipsen, Janssen, Merck Serono, MSD, Novartis, Pfizer
Consulting or Advisory Role: Apogepha, Bayer, BMS GmbH & Co KG, Ipsen, Janssen, Pfizer
Travel, Accommodations, Expenses: AstraZeneca, Bayer, Ipsen, Janssen, Pfizer

Can Aydogdu

Travel, Accommodations, Expenses: Ipsen, Eisai

Jozefina Casuscelli

Research Funding: AstraZeneca (Inst), MSD Oncology (Inst)

Expert Testimony: Janssen Cilag, MSD Oncology, Astellas Pharma

Travel, Accommodations, Expenses: Bayer, Janssen Oncology, Merck KGaA, Pfizer

Theresa Mokry

Honoraria: Bayer, Bracco Diagnostics, Deutsche Röntgengesellschaft, AKD Congress + Events

Research Funding: Philips Healthcare (Inst)

Dora Niedersüß-Beke

Consulting or Advisory Role: MSD Oncology, BMS GmbH & Co KG

Speakers' Bureau: BMS GmbH & Co KG, MSD Oncology, Astellas Pharma, Ipsen

Research Funding: Astellas Pharma

Steffen Rausch

Honoraria: Merck, Merck/Pfizer, Advanced Accelerator Applications, Janssen, Astellas Pharma, Bayer, Amgen, Ipsen, Bristol Myers Squibb/Sanofi

Consulting or Advisory Role: Ambu, Merck/Pfizer, Bayer, Bristol Myers Squibb/Sanofi, Eisai

Speakers' Bureau: Bayer

Research Funding: Ambu

Travel, Accommodations, Expenses: Janssen, Ipsen, Bayer, Merck/Pfizer

Dimo Dietrich

Research Funding: Novartis (Inst)

Patents, Royalties, Other Intellectual Property: Patents (licensed to Qiagen)

Jonas Saal

Travel, Accommodations, Expenses: Janssen

Manuel Ritter

Honoraria: Medac, Medac, Janssen Oncology

Research Funding: Procept Biorobotics (Inst)

Travel, Accommodations, Expenses: Medac

Joshua Meeks

Honoraria: Janssen, Merck, AstraZeneca, incyte, Urogen pharma, Prokarium, Imvax, Astellas Pharma, Pfizer

Research Funding: Epizyme, Merck Sharp & Dohme

Patents, Royalties, Other Intellectual Property: NMIBC genetic classifier (Inst), TCGA Classifier (Inst)

Other Relationship: Olympus

Francisco E. Vera Badillo

Consulting or Advisory Role: Bayer, AstraZeneca, Janssen Oncology, Merck, Bayer, AstraZeneca, Janssen Oncology, Janssen Oncology, Merck, Merck Serono

Research Funding: AstraZeneca/MedImmune (Inst), Janssen Oncology (Inst)

Travel, Accommodations, Expenses: Janssen Oncology

Joost Boormans

Consulting or Advisory Role: Bristol Myers Squibb/Sanofi, Janssen, MSD, ISMAR Health Care, Merck KGaA

Research Funding: Merck KGaA, Vitrosan, Janssen

Kerstin Junker

Stock and Other Ownership Interests: Bayer

Honoraria: Ipsen

Arndt Hartmann

Honoraria: BMS, MSD, Roche, AstraZeneca, Boehringer Ingelheim, Abbvie, Janssen-Cilag, Ipsen

Consulting or Advisory Role: Bristol Myers Squibb, MSD, Roche, Cepheid, Qiagen, Janssen-Cilag, AstraZeneca, Ipsen, NanoString Technologies, Illumina, 3DHISTECH, Diaceutics

Research Funding: Cepheid, BioNTech, Roche, Janssen-Cilag, NanoString Technologies, AstraZeneca, Owkin (Inst), PhADon (Inst)

Expert Testimony: NanoString Technologies

Viktor Grünwald

Employment: University Hospital Essen

Stock and Other Ownership Interests: MSD, Bristol Myers Squibb, AstraZeneca, Genmab, Bicycle Therapeutics

Honoraria: Bristol Myers Squibb, Pfizer, Ipsen, Eisai, MSD Oncology, Merck Serono, AstraZeneca, Janssen-Cilag, Advanced Accelerator Applications/Novartis, Apogepha, Ono Pharmaceutical, Astellas Pharma, Amgen

Consulting or Advisory Role: Bristol Myers Squibb, Pfizer, Novartis, MSD Oncology, Ipsen, Janssen-Cilag, Eisai, Debiopharm Group, PCI Biotech, Gilead Sciences, Cureteq, Oncorena, SyntheKine

Research Funding: Amgen (Inst), MSD Oncology (Inst), BMS (Inst), Seagen (Inst), Ipsen (Inst), Gilead Sciences (Inst), Bicycle Therapeutics (Inst)

Travel, Accommodations, Expenses: Pfizer, AstraZeneca, Janssen, Merck Serono, Ipsen

Michael Hölzel

Stock and Other Ownership Interests: Bicycle Therapeutics, Daiichi Sankyo/UCB Japan, immatics

Honoraria: Novartis, Bristol Myers Squibb/Roche, TME Pharma

Consulting or Advisory Role: TME Pharma, Novartis

Research Funding: TME Pharma

Patents, Royalties, Other Intellectual Property: EP 23 000 076.2 and EP 23 000 075.4 patent applications related to biomarkers for NOX-A12 therapy

Travel, Accommodations, Expenses: TME Pharma

Markus Eckstein

Employment: Diaceutics

Honoraria: AstraZeneca, Roche, Astellas Pharma, Genomic Health, Janssen-Cilag, Owkin, Diaceutics

Consulting or Advisory Role: AstraZeneca, Janssen-Cilag, Genomic Health, Diaceutics, Gilead Sciences, Owkin, MSD Oncology

Speakers' Bureau: Diaceutics, Roche, AstraZeneca, MSD, Astellas Pharma

Research Funding: STRATIFYER Molecular Pathology, Janssen, AstraZeneca/MedImmune, AstraZeneca/MedImmune, Owkin, Gilead Sciences

Travel, Accommodations, Expenses: AstraZeneca, Roche, MSD, Janssen-Cilag, Genomic Health, Diaceutics, Astellas Pharma

No other potential conflicts of interest were reported.

APPENDIX

TABLE A1. Baseline Characteristics of the mUC-EV Cohort

Characteristic	Nonamplified (n = 80)	Amplified (n = 28)	<i>P</i> ^a
Sex, No. (%)			.043
Male	56 (70)	25 (89)	
Female	24 (30)	3 (11)	
Age, years			.2
Median (IQR)	68, (58-73)	69, (61-75)	
Range	33-89	55-89	
ECOG, No. (%)			.9
0	26 (33)	10 (36)	
1	43 (54)	14 (50)	
≥2	10 (13)	4 (14)	
Hemoglobin, g/dL, No. (%)			.6
≥10	76 (95)	28 (100)	
<10	4 (5.0)	0 (0)	
Liver metastases, No. (%)			.011
No	51 (64)	25 (89)	
Yes	29 (36)	3 (11)	

NOTE. Significant *P* values are highlighted in bold.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; mUC-EV, metastatic urothelial cancer-enfortumab vedotin.

^aPearson's chi-squared test; Wilcoxon rank-sum test; Fisher's exact test.

TABLE A2. Baseline Characteristics of mUC-Non-EV

Characteristic	Nonamplified (n = 76)	Amplified (n = 27)	<i>P</i> ^a
Sex, No. (%)			.001
Male	53 (70)	27 (100)	
Female	23 (30)	0 (0)	
Age, years			.069
Median (IQR)	67 (56-72)	71 (62-75)	
Range	39-82	25-85	

NOTE. Significant *P* values are highlighted in bold.

Abbreviation: mUC-Non-EV, metastatic urothelial cancer-non enfortumab vedotin.

^aPearson's chi-squared test; Wilcoxon rank-sum test.

TABLE A3. Baseline Characteristics of TCGA-BCLA Cohort

Characteristic	Nonamplified, n = 336	Amplified, n = 72	<i>P</i> ^a
Sex, No. (%)			.15
Male	243 (72)	58 (81)	
Female	93 (28)	14 (19)	
Age, years			.013
Median (IQR)	68 (60-75)	73 (66-78)	
Range	34-90	44-88	

NOTE. Significant *P* values are highlighted in bold.

Abbreviation: TCGA-BCLA, The Cancer Genome Atlas - Bladder Cancer.

^aPearson's chi-squared test; Wilcoxon rank-sum test.




FIG A1. Illustration of copy number variation profiles derived by Illumina SNP arrays. Upper panel: *NECTIN4* nonamplified tumor profile; lower panel: *NECTIN4* amplified tumor profile. The *NECTIN4* gene location on Chr. 1 shows higher copy numbers in the amplified tumors. Chr.1, chromosome 1; SNP, single nucleotide polymorphisms.




FIG A2. PFS (A) and OS (B) upon initiation of EV treatment stratified by presence of *NECTIN4* gene amplification versus high membranous *NECTIN4* protein expression without *NECTIN4* gene amplification. EV, enfortumab vedotin; OS, overall survival; PFS, progression-free survival.




FIG A3. (A) Disease-specific survival of $n = 393$ patients of the TCGA-BLCA cohort stratified by copy number alterations of *NECTIN4* (data were missing for 14 patients). (B) Overall survival of $n = 407$ patients of the TCGA-BLCA cohort stratified by copy number alterations of *NECTIN4*. TCGA-BLCA, The Cancer Genome Atlas-bladder cancer.




FIG A4. (A) *NECTIN4* mRNA expression (log2 normalized RSEM values) in TCGA-BRCA cohort stratified by *NECTIN4* copy number alterations. (B) *NECTIN4* protein expression levels (Z-score scaled results from RPPA) in TCGA-BRCA cohort stratified by *NECTIN4* copy number alterations. (C) *NECTIN4* mRNA expression (log2 normalized RSEM values) in TCGA-LUAD cohort stratified by *NECTIN4* copy number alterations. NS, not significant; RPPA, reverse-phase protein arrays; TCGA-BRCA, The Cancer Genome Atlas breast cancer; TCGA-LUAD; The Cancer Genome Atlas lung adenocarcinoma.